Covid-19 Infection: Prerequisites for New Areas of Research

α
Surayyo Z. Yuldasheva
Surayyo Z. Yuldasheva
σ
Iskandar R. Mavlanov
Iskandar R. Mavlanov
ρ
Аbdurashid Kh. Аshirmetov
Аbdurashid Kh. Аshirmetov
Ѡ
Ziyodulla I.  Mavlanov
Ziyodulla I. Mavlanov
¥
Gavkhar J. Jarylkasimova
Gavkhar J. Jarylkasimova

Send Message

To: Author

Covid-19 Infection: Prerequisites for New Areas of Research

Article Fingerprint

ReserarchID

8LIR7

Covid-19 Infection: Prerequisites for New Areas of Research Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

The pandemic of COVID-19 infection caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) has posed a significant threat to global health. Now, we have witnessed an unsurpassed increase in the number of clinical trials worldwide. In clinical trials old and new drugs are tested as potential treatments either for their direct anti-viral activity, or for their ability to provide management of respiratory and cardiovascular symptoms and complications, characteristic of COVID-19. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Such a strategy is likely to give rise to a range of safety and efficacy challenges that could be addressed through preliminary pharmaco-genetic research on identification of risk groups for personification of therapy approach. Addressing the personification of drug treatment COVID-19 becomes an urgent need to interpret the conflicting results of clinical trials and establish the apparent efficacy of any particular drug.

References

19 Cites in Article
  1. B Mccloskey,D Heymann (2020). SARS to novel coronavirus: old lessons and new lessons.
  2. M Majumder,K Mandl (2020). Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility.
  3. W Liu,J Morse,T Lalonde (2020). Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV.
  4. Markus Hoffmann,Hannah Kleine-Weber,Nadine Krüger,Marcel Müller,Christian Drosten,Stefan Pöhlmann (2020). The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells.
  5. Taisheng Li,Hongzhou Lu,Wenhong Zhang (2020). Clinical observation and management of COVID-19 patients.
  6. Zsuzsanna Varga,Andreas Flammer,Peter Steiger,Martina Haberecker,Rea Andermatt,Annelies Zinkernagel,Mandeep Mehra,Reto Schuepbach,Frank Ruschitzka,Holger Moch (2020). Endothelial cell infection and endotheliitis in COVID-19.
  7. Maria Dalamaga,Irene Karampela,Christos Mantzoros (2020). Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?.
  8. Felice Rivellese,Edoardo Prediletto (2020). ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia.
  9. C Qin,L Zhou,Z Hu (2020). Dysregulation of immune response in patients with COVID-19 in Wuhan.
  10. Geng Li,Yaohua Fan,Yanni Lai,Tiantian Han,Zonghui Li,Peiwen Zhou,Pan Pan,Wenbiao Wang,Dingwen Hu,Xiaohong Liu,Qiwei Zhang,Jianguo Wu (2020). Coronavirus infections and immune responses.
  11. E Prompetchara,C Ketloy,T Palaga (2020). Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.
  12. Allison Totura,Ralph Baric (2012). SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon.
  13. Savannah Pedersen,Ya-Chi Ho (2020). SARS-CoV-2: a storm is raging.
  14. H Harapan,N Itoh,A Yufika (2020). Coronavirus disease 2019 (COVID-19): A literature review.
  15. W Liu,H Li (2020). COVID-19: Attacks the 1-Beta chain of hemoglobin and captures the Porphyrin to inhibit human Heme metabolism.
  16. H Drakesmith,A Prentice (2008). Viral infection and iron metabolism.
  17. Marianne Wessling-Resnick (2010). Iron Homeostasis and the Inflammatory Response.
  18. Md Ali,Richard Kim,Alexandra Brown,Chantal Donovan,Kanth Vanka,Jemma Mayall,Gang Liu,Amber Pillar,Bernadette Jones‐freeman,Dikaia Xenaki,Theo Borghuis,Rafia Karim,James Pinkerton,Ritambhara Aryal,Moones Heidari,Kristy Martin,Janette Burgess,Brian Oliver,Debbie Trinder,Daniel Johnstone,Elizabeth Milward,Philip Hansbro,Jay Horvat (2020). Critical role for iron accumulation in the pathogenesis of fibrotic lung disease.
  19. Ennio Favalli,Francesca Ingegnoli,Orazio De Lucia,Gilberto Cincinelli,Rolando Cimaz,Roberto Caporali (2020). COVID-19 infection and rheumatoid arthritis: Faraway, so close!.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Surayyo Z. Yuldasheva. 2021. \u201cCovid-19 Infection: Prerequisites for New Areas of Research\u201d. Global Journal of Medical Research - K: Interdisciplinary GJMR-K Volume 20 (GJMR Volume 20 Issue K14): .

Download Citation

Issue Cover
GJMR Volume 20 Issue K14
Pg. 35- 38
Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-K Classification: NLMC Code: WC 505
Version of record

v1.2

Issue date

January 6, 2021

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 2178
Total Downloads: 1058
2026 Trends
Related Research

Published Article

The pandemic of COVID-19 infection caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) has posed a significant threat to global health. Now, we have witnessed an unsurpassed increase in the number of clinical trials worldwide. In clinical trials old and new drugs are tested as potential treatments either for their direct anti-viral activity, or for their ability to provide management of respiratory and cardiovascular symptoms and complications, characteristic of COVID-19. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Such a strategy is likely to give rise to a range of safety and efficacy challenges that could be addressed through preliminary pharmaco-genetic research on identification of risk groups for personification of therapy approach. Addressing the personification of drug treatment COVID-19 becomes an urgent need to interpret the conflicting results of clinical trials and establish the apparent efficacy of any particular drug.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Covid-19 Infection: Prerequisites for New Areas of Research

Iskandar R. Mavlanov
Iskandar R. Mavlanov
Аbdurashid Kh. Аshirmetov
Аbdurashid Kh. Аshirmetov
Ziyodulla I.  Mavlanov
Ziyodulla I. Mavlanov
Gavkhar J. Jarylkasimova
Gavkhar J. Jarylkasimova

Research Journals